Abstract

Sphingosine‑1‑phosphate (S1P) and its five G protein‑coupled receptors (S1PR1‑S1PR5) regulate a broad range of processes that shape cancer progression, including proliferation, survival, angiogenesis, immune evasion and metastatic dissemination. Under physiological conditions, this signaling axis contributes to vascular integrity, immune cell trafficking and tissue homeostasis. In cancer, however, its output is not solely determined by ligand abundances. Rather, tumors reprogram the S1P‑S1PR axis at a number of levels, coupling altered S1P production with receptor‑specific changes in expression, localization and the signaling state to generate context‑dependent malignant phenotypes. The present review provided a receptor‑resolved synthesis of S1PR functions in cancer and examined the mechanisms that underlie pathway dysregulation, including transcriptional activation, epigenetic remodeling, microRNA loss, post‑translational modifications and altered receptor trafficking and compartmentalization. It further discussed how metabolic amplification of S1P availability cooperates with receptor‑level rewiring to sustain tumor progression, microenvironmental remodeling and therapeutic resistance. This framework positions the S1P‑S1PR axis as a dynamically reprogrammed signaling network and highlights therapeutic strategies that concurrently target S1P production and receptor‑mediated signaling as promising avenues for more‑precise, biomarker‑informed cancer treatment.